Black Rock Inc. Hookipa Pharma Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Hookipa Pharma Inc. stock. As of the latest transaction made, Black Rock Inc. holds 289,293 shares of HOOK stock, worth $228,541. This represents 0.0% of its overall portfolio holdings.

Number of Shares

289,293

Previous 294,272 1.69%

Holding current value

$228,541

Previous $238,000 13.87%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.61 - $0.83 $3,037 - $4,132	-4,979 Reduced 1.69%	289,293 $205,000
Q4 2023 Feb 13, 2024	SELL	$0.42 - $0.86 $406 - $832	-968 Reduced 0.33%	294,272 $238,000
Q3 2023 Nov 13, 2023	BUY	$0.58 - $0.91 $21,936 - $34,418	37,822 Added 14.69%	295,240 $183,000
Q2 2023 Aug 11, 2023	SELL	$0.71 - $1.97 $57,691 - $160,074	-81,256 Reduced 23.99%	257,418 $226,000
Q1 2023 May 12, 2023	BUY	$0.72 - $1.03 $2,582 - $3,694	3,587 Added 1.07%	338,674 $250,000

Q4 2022 Feb 13, 2023	BUY	$0.73 - $1.31 $1,681 - $3,016	2,303 Added 0.69%	335,087 $271,000
Q3 2022 Nov 14, 2022	BUY	$1.27 - $1.87 $5,060 - $7,451	3,985 Added 1.21%	332,784 $445,000
Q2 2022 Aug 12, 2022	SELL	$1.33 - $2.31 $1.1 Million - $1.92 Million	-830,373 Reduced 71.64%	328,799 $537,000
Q1 2022 May 12, 2022	SELL	$1.26 - $2.52 $67,195 - $134,391	-53,330 Reduced 4.4%	1,159,172 $2.64 Million
Q4 2021 Feb 10, 2022	BUY	$2.33 - $5.94 $370,442 - $944,388	158,988 Added 15.09%	1,212,502 $2.83 Million
Q3 2021 Nov 09, 2021	BUY	$5.89 - $9.35 $17,628 - $27,984	2,993 Added 0.28%	1,053,514 $6.2 Million
Q2 2021 Aug 11, 2021	BUY	$9.16 - $19.51 $9.62 Million - $20.5 Million	1,050,521 New	1,050,521 $9.62 Million

Others Institutions Holding HOOK

# of Institutions

Shares Held

32.5M

Call Options Held

105K

Put Options Held

43.6K

View Full List

About HOOKIPA Pharma Inc.

Ticker HOOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,654,500
Market Cap $40.8M
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...

More about HOOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account